Discovery of Cell-Permeable Allosteric Inhibitors of Liver Pyruvate Kinase: Design and Synthesis of Sulfone-Based Urolithins
Shazia Iqbal, Md. Zahidul Islam, Sajda Ashraf, Amal A. AL-Sharabi, Essam Hanashalshahaby, Woonghee Kim, Cheng Zhang, Mathias Uhlen, Adil Mardinoglu, Mehmet Ozcan, Jan Boren, Hasan Turkez
article (Uluslararası, Hakemli) | Yazar(lar): Shazia Iqbal, Md. Zahidul Islam, Sajda Ashraf, Amal A. AL-Sharabi, Essam Hanashalshahaby, Woonghee Kim, Cheng Zhang, Mathias Uhlen, Adil Mardinoglu, Mehmet Ozcan, Jan Boren, Hasan Turkez | Yıl: 2024 | Dergi/Kurum: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | İndeks: WOS.SC
Metabolic dysfunction-associated fatty liver disease (MAFLD) presents a significant global health challenge, characterized by the accumulation of liver fat and impacting a considerable portion of the worldwide population. Despite its widespread occurrence, effective treatments for MAFLD are limited. The liver-specific isoform of pyruvate kinase (PKL) has been identified as a promising target for developing MAFLD therapies. Urolithin C, an allosteric inhibitor of PKL, has shown potential in preliminary studies. Expanding upon this groundwork, our study delved into delineating the structure-activity relationship of urolithin C via the synthesis of sulfone-based urolithin analogs. Our results highlight that incorporating a sulfone moiety leads to substantial PKL inhibition, with additional catechol moieties further enhancing this effect. Despite modest improvements in liver cell lines, there was a significant increase in inhibition observed in HepG2 cell lysates. Specifically, compounds 15d, 9d, 15e, 18a, 12d, and 15a displayed promising IC50 values ranging from 4.3 mu M to 18.7 mu M. Notably, compound 15e not only demonstrated a decrease in PKL activity and triacylglycerol (TAG) content but also showed efficient cellular uptake. These findings position compound 15e as a promising candidate for pharmacological MAFLD treatment, warranting further research and studies.